CA-OMNI-CONVERSION
22.4.2021 06:10:08 CEST | Business Wire | Press release
Today, OMNI Conversion Technologies Inc. (OMNI CT) announced the first sale of its unprecedented waste to hydrogen product. The Larsen and Lam Climate Initiative, a foundation backed by philanthropists Chris Larsen and Lyna Lam, has committed $35 million to bring this ground-breaking technology to production in the fight against climate change. The first commercial plant in production from OMNI CT will use unsorted non-recyclable Municipal Solid Waste (MSW), which is currently disposed of in landfills, to produce negative carbon hydrogen in California.
New technologies are essential in the fight against climate change. While low-cost solar electricity was a dream only a decade ago, its impact today is far-reaching. The Larsen and Lam Climate Initiative investment will accelerate the global adoption of OMNI CT technology.
”Low or zero CO2 fuels are critical to achieving a decarbonized economy. OMNI CT has created a first-of-its-kind product that can have a global and immediate impact. This is why we are excited to work with their team to bring this technology to market in California as our first project from the Larsen and Lam Climate Initiative,” said Chris Larsen, Co-Founder of the Larsen and Lam Climate Initiative and Ripple.
“With surging global interest in hydrogen and biofuels and as the urgency grows around the climate change crisis, it’s an opportune time to be launching our product into the fight against climate change. We’ve spent 15 years and $400 million perfecting it. We’re thrilled to be working with the Larsen and Lam Climate Initiative who not only understand but share our vision for the future,” said Rod Bryden, CEO of OMNI CT.
Professor Daniel Kammen, Chair of the Energy and Resources Group at the University of California, Berkeley, commented that zero-carbon fuels are a critical part of the aggressive path to a clean economy. As California looks to build a vibrant zero-carbon economy, the Omni technology is an exciting addition that will solve multiple problems at once.
The Omni 200™ GPRS™ waste to hydrogen product can produce around 5000 tonnes of negative carbon hydrogen each year, from 200 tonnes a day of unsorted non-recyclable garbage. Hydrogen is produced in the city where it is needed and the garbage is diverted from landfill to OMNI CT and eliminated with no air emissions and nothing left for disposal. Energy in the garbage replaces electricity otherwise required to make green hydrogen. The circular hydrogen produced could operate some 550 city buses running on hydrogen at a cost less than the current cost of using gasoline or diesel.
The purchase was funded and signed on April 21, 2021 with the goal of being in production in California converting Municipal Solid Waste to hydrogen by the end of 2023.
About OMNI CT
OMNI CT is an Ottawa Canada-based company that has developed a proprietary technology by designing, building, testing, and operating a complete commercial demonstration plant from 2007-2014. The patented process converts any solid energetic material into OmniSyngas™ to produce clean green hydrogen, biofuels, synthetic natural gas, chemicals or electricity for the circular economy.
OMNI CT’s robust efficient OMNI200™ GPRS™ is providing a unique solution to achieving decarbonization targets.
The OMNI200™ Gasification & Plasma Refining System (GPRS™)
The OMNI200™ GPRS™ unit is proven at industrial scale. It is a complete integrated system, delivered to site in large modules, rather than stick-built. It receives and converts at a rate of 200 tonnes per day (67,000 tonnes per year) a wide variety and mix of energetic wastes into clean consistent syngas with a predictable heating value and composition. The H2/CO ratio can be tailored to the final application. Multiple units can be readily combined for larger plants.
OmniSyngas™
OmniSyngas™ is a precursor to the production of hydrogen and biofuels. Municipal solid waste has more than 50% biogenic content. This will produce green fuels and avoid methane from sending waste to landfills. Since methane has 25x the GHG effect of CO2, these fuels can be produced with a negative carbon footprint. Further reduction is possible by capturing and storing the CO2 in the syngas.
For additional details on Omni CT’s product: Download Product Description
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421006131/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom